PreprintPublic domainZenodo (CERN European Organization for Nuclear Research)
Study 12 — The COVID-19 Dexamethasone Programme as Real-World Validation of Corticosteroid-Strongyloides Risk
- 1Independent Researcher
Abstract
Draft pre-print — Hidden Infections research series. AI-assisted. CC0 public domain. Reproducibility data package included.
Related
- FAERS Pharmacovigilance: Strongyloides stercoralis Adverse Event Disproportionality in Corticosteroid Recipients
- Comparative 28-day Outcomes of Pulse-Dose Methylprednisolone versus Prolonged Low-Dose Dexamethasone in Hospitalized COVID-19 Pneumonia: A Cohort Study.
- Development and content validation of a risk-stratified nursing intervention programme for the prevention of healthcare-associated infections
- Impact of COVID-19 pandemic on childhood immunization coverage in Indonesia: lesson learned from a nationwide analysis of the Expanded Programme on Immunization
- Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation
BibTeX
@misc{webb2026study,
title = {{Study 12 — The COVID-19 Dexamethasone Programme as Real-World Validation of Corticosteroid-Strongyloides Risk}},
author = {Marcus Webb},
howpublished = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
month = may,
doi = {10.5281/zenodo.20402646},
url = {https://doi.org/10.5281/zenodo.20402646},
note = {Public domain},
}
RIS
TY - UNPB
TI - Study 12 — The COVID-19 Dexamethasone Programme as Real-World Validation of Corticosteroid-Strongyloides Risk
AU - Marcus Webb
PY - 2026
DA - 2026/05/27
PB - Zenodo (CERN European Organization for Nuclear Research)
DO - 10.5281/zenodo.20402646
UR - https://doi.org/10.5281/zenodo.20402646
AB - Draft pre-print — Hidden Infections research series. AI-assisted. CC0 public domain. Reproducibility data package included.
ER -